Advertisement

Topics

Companies Related to "Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia" [Most Relevant Company Matches] RSS

11:10 EDT 19th October 2018 | BioPortfolio

Here are the most relevant search results for "Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia" found in our extensive corporate database of over 50,000 company records.

Showing "Bryostatin Cytarabine Treating Patients With Relapsed Acute Myelogenous" Companies 1–25 of 4,300+

Relevant

Callisto Pharmaceuticals, Inc.

Callisto Pharmaceuticals, Inc., is a publicly traded biotechnology company on the American Stock Exchange (AMEX:KAL) and Frankfurt Exchange (CA4). Callisto's primary focus is the clinical development of two drugs to treat cancer, L-Annamycin for relapsed leukemia and Atiprimod for relapsed multiple myeloma (MM) and bone resorption. L-Annamycin, a drug from the anthracycline family, earlier complet...


Cellerant Therapeutics Inc.

Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant’s lead product, CLT-008 is currently in Phase 1 clinical trials evaluating safety in pa...

bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting


Verastem Oncology

Verastem, Inc. (Nasdaq:VSTM), operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients. Verastem Oncology is currently developing duvelisib, a dual inhibitor of PI3K-delta and PI3K-gamma, which has successfully met its primary endpoint i...

Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigat...

Nodality, Inc.

Nodality develops and commercializes the next generation of personal diagnostic tests by characterizing cell signaling pathways in defined cellular sub-populations of malignant and normal cells. The South San Francisco based company applies proprietary multiparametric Single Cell Network Profiling (SCNP) technology to develop highly predictive biological ...

SGX Pharmaceuticals

SGX Pharmaceuticals (formerly Structural GenomiX) is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics.We are developing Troxatyl™, a novel compound that is currently in a pivotal Phase II/III clinical trial for the third-line treatment of Acute Myelogenous Leukemia (AML). We also plan to develop Troxatyl in combination with Ara...

Athera Biotechnologies AB

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera is a Karolinska Development AB (publ) portfolio co...

Athera Biotechnologies & ALPCO

Athera has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Athera is a Karolinska Development AB (publ) portfolio co...

Arginox Pharmaceuticals, Inc

Arginox Pharmaceuticals is an emerging specialty biopharmaceutical company focusing on the discovery and development of breakthrough drugs for treating hospitalized patients. The company's initial area of research is directed at nitric oxide (NO), which has been shown in Nobel prize-winning research to play a role in a range of physiologic functions. Arginox is leading the way in developing drugs ...

TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company which has been committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal has been to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migr...

Cigna Corporation and Piedmont Healthcare

Piedmont Healthcare is a private, not-for-profit organization that serves nearly two million patients primarily in North Georgia communities but also across the state. The six hospitals include Piedmont Atlanta Hospital, a 529-bed acute-care hospital in Buckhead; Piedmont Fayette Hospital, a 172-bed, acute-care community hospital in Fayetteville; Piedmont ...

Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. We have two small molecule anticancer compounds under evaluation in human clinical trials. Our product, Cloretazine® (VNP40101M) is currently being studied for the treatment of acute myelogenous leukemia (AML), including a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition a trial of Cloretazine® ...

Rasna Therapeutics , Inc.

Rasna Therapeutics, Inc. is a biotechnology company focused primarily on the high unmet need that exists for leukemias. Rasna’s primary indication is acute myeloid leukemia (AML) which may be fatal within weeks to months, has a 5-year survival rate of only about 25% and very poor prospects for long-term survival of patients. The company has a balanced...

Rasna Therapeutics, Inc.

Rasna Therapeutics, Inc. is a development stage biotechnology company focused primarily on the high unmet need that exists for leukemias. Rasna’s primary indication is acute myeloid leukemia (AML) which may be fatal within weeks to months, has a 5-year survival rate of only about 25% and very poor prospects for long-term survival of patients. The comp...

Promise Healthcare, Inc.

Based in Boca Raton, Florida, Promise Healthcare is one of the largest long-term acute care (LTAC) hospital organizations in the country. With more than 2,000 staff members and 13 hospitals nationwide, Promise Hospitals utilize an interdisciplinary approach to healing and wellness. Promise’s distinctive LTAC environment provides acute medical care and ...

Celator Pharmaceuticals

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a na...

OPi Ltd

Founded in 1999, OPi is a European integrated biopharmaceutical company whose mission is to develop and market pharmaceuticals (small molecules and biologicals) aimed at treating patients suffering from rare and severe diseases. OPi’s primary focus is onco-haematology, with a R&D portfolio of monoclonal antibodies at various stages of development, and with Kidrolase® (L-asparaginase) and Erwina...

Celator Pharmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex®, the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic ...

Promise Healthcare

Headquartered in Boca Raton, Florida, Promise Healthcare, Inc. (www.promisehealthcare.com) is one of the largest long-term acute care (LTAC) hospital organizations in the country. With more than 5,000 staff members and 19 health care facilities nationwide, Promise hospitals utilize an interdisciplinary approach to healing and wellness. Promise’s distinctive ...

NeuroPace, Inc.

NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders by responsive brain stimulation. The company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide. Patients are currently being enrolled in a clinical trial of the company's Responsive N...

CerebralRx

Based in Yehud, Israel, CerebralRx was founded in 2010 as a spin-off of BioControl Medical to develop breakthrough implantable neuromodulation systems for the treatment of autonomic nervous system-related neurological disorders. The company’s flagship product is the FitNeS system, an implantable vagus nerve stimulation device for treating patients wit...

Ocera Therapeutics, Inc.

Ocera Therapeutics, based in San Diego, California, USA, is a privately held biopharmaceutical company focused on the development and commercialization of proprietary compounds to treat acute and chronic liver diseases and a broad range of gastrointestinal disorders. In addition to AST-120, Ocera is developing OCR-002, an ammonia detoxification agent, for the treatment of hospitalized patients wit...

Allos Therapeutics, Inc.

Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN® (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is the first and only drug approved in t...

Miracor Medical Systems GmbH

Based in Vienna, Austria, privately held Miracor is commercializing a unique and potentially disruptive technology, PICSO®, for acute coronary syndrome (ACS), heart failure, and cardiac surgery patients. The Company’s objective is to establish PICSO® as the standard of care for heart attack patients, thereby improving their quality of life. The ...


More From BioPortfolio on "Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks